缺氧诱导因子脯氨酰羟化酶抑制剂:慢性肾脏病患者贫血的潜在新疗法
红细胞生成刺激剂(ESAs)自1989年以来一直是慢性肾脏病(CKD)贫血的标准治疗,但存在心血管事件和血管通路血栓形成等安全性担忧。缺氧诱导因子(HIF)脯氨酰羟化酶(PH)抑制剂是一类口服新药,通过稳定HIF复合物刺激内源性促红细胞生成素产生并改善铁动员;其诱导的促红细胞生成素水平较低但更稳定,可能在相当血红蛋白水平下减少不良心血管效应,但尚未在长期临床试验中证实,且长期使用对肿瘤生长的潜在影响值得关注。美国有4种此类药物正在进行2期和3期临床试验,本报告对HIF-PH抑制剂及其在CKD贫血管理中的潜在临床效用进行了重点综述。
要点
- ESAs自1989年起为CKD贫血标准治疗,但存在心血管事件及血管通路血栓形成等安全性担忧。
- HIF-PH抑制剂口服给药,可稳定HIF复合物、刺激内源性促红细胞生成素产生并改善铁动员。
- HIF-PH抑制剂可能减少不良心血管效应,但尚未在长期临床试验中证实,且需关注对肿瘤生长的潜在影响。
核心结论
- HIF-PH抑制剂是CKD贫血的潜在新治疗类别,口服给药,可刺激内源性促红细胞生成素产生并改善铁动员,但长期心血管安全性和对肿瘤生长的影响尚未证实。
研究设计与样本
- 本文为聚焦综述,纳入美国正在进行的2期和3期临床试验的4种HIF-PH抑制剂。
主要发现
- ESAs可升高血红蛋白、减少输血需求,但增加心血管事件和血管通路血栓形成的发生。
- HIF-PH抑制剂通过稳定HIF复合物刺激内源性促红细胞生成素产生,即使在终末期肾病患者中亦有效。
- HIF-PH抑制剂改善铁向骨髓的动员,且为口服给药,可能对非血液透析患者更便利。
- 与ESAs相比,HIF-PH抑制剂诱导的血液促红细胞生成素水平较低但更稳定,可能在相当血红蛋白水平下与较少不良心血管效应相关,但尚未在长期临床试验中证实。
临床怎么用
- 原文未据此给出推荐。
局限性
- HIF-PH抑制剂在相当血红蛋白水平下减少不良心血管效应的可能性尚未在长期临床试验中证实。
- 长期使用HIF-PH抑制剂对肿瘤生长的可能影响是重要担忧。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Erythropoiesis-stimulating agents (ESAs) increase hemoglobin levels, reduce transfusion requirements, and have been the standard of treatment for anemia in patients with chronic kidney disease (CKD) since 1989. Many safety concerns have emerged regarding the use of ESAs, including an increased occurrence of cardiovascular events and vascular access thrombosis. Hypoxia-inducible factor (HIF) prolyl hydroxylase (PH) enzyme inhibitors are a new class of agents for the treatment of anemia in CKD. These agents work by stabilizing the HIF complex and stimulating endogenous erythropoietin production even in patients with end-stage kidney disease. HIF-PH inhibitors improve iron mobilization to the bone marrow. They are administered orally, which may be a more favorable route for patients not undergoing hemodialysis. By inducing considerably lower but more consistent blood erythropoietin levels than ESAs, HIF-PH inhibitors may be associated with fewer adverse cardiovascular effects at comparable hemoglobin levels, although this has yet to be proved in long-term clinical trials. One significant concern regarding the long-term use of these agents is their possible effect on tumor growth. There are 4 such agents undergoing phase 2 and 3 clinical trials in the United States; this report provides a focused review of HIF-PH inhibitors and their potential clinical utility in the management of anemia of CKD.
引用
- Gupta N, Wish JB. Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors: A Potential New Treatment for Anemia in Patients With CKD. Am J Kidney Dis. 2017. PMID: 28242135. doi:10.1053/j.ajkd.2016.12.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。